Alkem Laboratories Crecimiento futuro

Future controles de criterios 1/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Alkem Laboratories de 10.6% y 9.4% por año respectivamente. Se prevé que el BPA crezca en un 10.5% al año. Se espera que la rentabilidad financiera sea de 18.6% en 3 años.

Información clave

10.6%

Tasa de crecimiento de los beneficios

10.5%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	18.3%
Tasa de crecimiento de los ingresos	9.4%
Rentabilidad financiera futura	18.6%
Cobertura de analistas	Good
Última actualización	15 Nov 2024

Actualizaciones recientes sobre el crecimiento futuro

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Nov 16

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 27

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Jul 13

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jun 27

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Jun 13

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Jun 01

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

May 22

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Feb 13

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Jan 17

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Dec 27

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Sep 14

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Aug 02

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Jul 07

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

May 22

We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Mar 27

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Dec 26

These 4 Measures Indicate That Alkem Laboratories (NSE:ALKEM) Is Using Debt Reasonably Well

Sep 20

Alkem Laboratories' (NSE:ALKEM) Dividend Is Being Reduced To ₹4.00

Jul 27

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Jul 13

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Jun 11

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

May 23

Does This Valuation Of Alkem Laboratories Limited (NSE:ALKEM) Imply Investors Are Overpaying?

Mar 06

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Feb 21

Previsiones de crecimiento de beneficios e ingresos

NSEI:ALKEM - Estimaciones futuras de los analistas y datos financieros pasados (INR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
3/31/2027	161,346	27,516	19,790	23,269	19
3/31/2026	147,401	25,256	16,921	21,438	22
3/31/2025	133,577	22,434	15,906	25,062	22
9/30/2024	128,319	21,223	15,054	19,549	N/A
6/30/2024	127,317	20,542	N/A	N/A	N/A
3/31/2024	126,676	17,958	16,888	19,481	N/A
12/31/2023	126,344	15,732	N/A	N/A	N/A
9/30/2023	123,514	14,329	18,370	20,537	N/A
6/30/2023	119,906	11,433	N/A	N/A	N/A
3/31/2023	115,993	9,842	14,496	16,825	N/A
12/31/2022	111,805	10,208	N/A	N/A	N/A
9/30/2022	107,586	10,917	5,527	8,426	N/A
6/30/2022	104,792	13,051	N/A	N/A	N/A
3/31/2022	106,342	16,456	7,721	11,110	N/A
12/31/2021	103,425	17,780	N/A	N/A	N/A
9/30/2021	100,416	17,033	10,478	13,213	N/A
6/30/2021	96,044	16,311	N/A	N/A	N/A
3/31/2021	88,650	15,850	11,051	12,649	N/A
12/31/2020	87,218	15,338	N/A	N/A	N/A
9/30/2020	85,971	14,648	8,916	11,455	N/A
6/30/2020	84,984	13,636	N/A	N/A	N/A
3/31/2020	83,444	11,271	2,220	5,851	N/A
12/31/2019	81,484	11,057	N/A	N/A	N/A
9/30/2019	78,929	9,262	5,173	8,756	N/A
6/30/2019	75,478	8,098	N/A	N/A	N/A
3/31/2019	73,572	7,605	2,505	7,797	N/A
12/31/2018	70,157	6,602	N/A	N/A	N/A
9/30/2018	68,318	6,293	N/A	N/A	N/A
6/30/2018	67,788	6,955	N/A	N/A	N/A
3/31/2018	63,918	6,309	N/A	2,660	N/A
12/31/2017	60,044	7,009	N/A	N/A	N/A
9/30/2017	57,285	7,626	N/A	N/A	N/A
6/30/2017	55,019	7,248	N/A	N/A	N/A
3/31/2017	56,875	8,920	N/A	4,711	N/A
12/31/2016	56,933	7,732	N/A	N/A	N/A
9/30/2016	54,992	7,267	N/A	N/A	N/A
6/30/2016	52,419	7,108	N/A	N/A	N/A
3/31/2016	49,248	7,416	N/A	7,258	N/A
12/31/2015	47,975	8,189	N/A	N/A	N/A
9/30/2015	44,556	7,227	N/A	4,023	N/A
6/30/2015	40,459	5,781	N/A	N/A	N/A
3/31/2015	37,434	3,916	N/A	3,255	N/A
3/31/2014	31,191	4,353	N/A	2,900	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (10.6% al año) de ALKEM es superior a la tasa de ahorro (6.7%).

Beneficios vs. Mercado: Se prevé que los beneficios (10.6% al año) de ALKEM crezcan menos que el mercado Indian (17.9% al año).

Beneficios de alto crecimiento: Se prevé que los beneficios de ALKEM crezcan, pero no significativamente.

Ingresos vs. Mercado: Se prevé que los ingresos (9.4% al año) de ALKEM crezcan más despacio que el mercado de Indian (10.5% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 9.4% al año) de ALKEM crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de ALKEM sea baja dentro de 3 años (18.6%).

Alkem Laboratories Crecimiento futuro

Future controles de criterios 1/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Recent updates

Alkem Laboratories Limited Recorded A 5.4% Miss On Revenue: Analysts Are Revisiting Their Models

Here's Why We Think Alkem Laboratories (NSE:ALKEM) Is Well Worth Watching

Second quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alkem Laboratories Limited to Report Q2, 2025 Results on Nov 13, 2024

Cipla, Alkem Laboratories Reportedly in Final Lap to Buy SMT

Alkem Laboratories Limited Announces Retirement of Yogesh Kaushal as Senior Management Personnel

Alkem Laboratories Limited Approves Appointment of Rajeev Kher as an Independent Director

Alkem Labs Reportedly in Talks to Acquire Novartis India from Its Swiss Parent

What Alkem Laboratories Limited's (NSE:ALKEM) P/E Is Not Telling You

Alkem Reportedly Joins $3 Billion Race for JB Chem as Torrent Pauses Talks

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

KKR, TPG Capital, Apax Partners and Other PE Firms Reportedly Eye Purchase of Sahajanand Medical Technologies

Earnings Beat: Alkem Laboratories Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings: EPS and revenues miss analyst expectations

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2025 Results on Aug 09, 2024

Alkem Laboratories' (NSE:ALKEM) Dividend Will Be Reduced To ₹5.00

Alkem Laboratories Limited Announces Change in Management

Alkem Laboratories' (NSE:ALKEM) Shareholders Will Receive A Smaller Dividend Than Last Year

Less than half of directors are independent

Alkem Laboratories (NSE:ALKEM) Has Announced That Its Dividend Will Be Reduced To ₹5.00

Biosergen AB Receives the Final Permission Required to Test Lead Candidate BSG005 in Patients with Invasive Fungal Infection

Alkem Laboratories Limited (NSE:ALKEM) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Alkem Laboratories Limited, Annual General Meeting, Aug 30, 2024

Final dividend of ₹5.00 announced

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2024, Payable on and from 4 September, 2024

Full year 2024 earnings released: EPS: ₹150 (vs ₹82.31 in FY 2023)

Earnings Tell The Story For Alkem Laboratories Limited (NSE:ALKEM)

Alkem Laboratories Limited to Report Q4, 2024 Results on May 29, 2024

Consensus EPS estimates increase by 10%

Alkem Laboratories Limited (NSE:ALKEM) Just Reported And Analysts Have Been Lifting Their Price Targets

Price target increased by 9.5% to ₹4,523

Third quarter 2024 earnings released: EPS: ₹49.76 (vs ₹38.03 in 3Q 2023)

Alkem Laboratories Limited Approves Interim Dividend for Financial Year 2023-24 , Payable on 1 March, 2024

Investors Appear Satisfied With Alkem Laboratories Limited's (NSE:ALKEM) Prospects

Alkem Laboratories Limited Announces CFO Changes

Alkem Laboratories Limited Announces CFO Changes

We Think Alkem Laboratories (NSE:ALKEM) Can Manage Its Debt With Ease

Alkem Laboratories Limited Appoints Ashish Sehgal to Hold Senior Management Position in the Company Effective 15 December 2023

Alkem Laboratories Limited Submits Clinical Trial Application for First Patient Study with Bsg005 in Invasive Fungal Infections in India as A Rescue Therapy

Alkem Laboratories Limited Appoints Kaustav Banerjee to Hold Senior Management Position

Alkem Laboratories Appoints Sanchit Bansal to Senior Management Position

Alkem Laboratories Limited Appoints Madhurima Singh, Executive Director

Price target increased by 7.5% to ₹3,956

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited to Report Q2, 2024 Results on Nov 07, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Alkem Laboratories Limited Appoints Vikas Gupta as the Chief Executive Officer, Effective 22nd September, 2023

Is Alkem Laboratories (NSE:ALKEM) Using Too Much Debt?

Price target increased by 7.5% to ₹3,612

Upcoming dividend of ₹10.00 per share at 0.6% yield

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories Limited to Report Q1, 2024 Results on Aug 10, 2023

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Alkem Laboratories (NSE:ALKEM) Is Paying Out A Larger Dividend Than Last Year

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Alkem Laboratories Limited Recommends Final Dividend for Financial Year Ended March 31, 2023, Payable on and from August 30, 2023

Alkem Laboratories Limited, Annual General Meeting, Aug 25, 2023

Alkem Laboratories Limited to Report Q4, 2023 Results on May 19, 2023

We Think Alkem Laboratories (NSE:ALKEM) Can Stay On Top Of Its Debt

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Alkem Laboratories Limited Declares Special Dividend for the Financial Year 2022-2023, Payable Be on and from 01 March, 2023

Alkem Laboratories Limited Declares Interim Dividend for the Financial Year 2022-2023, Payable on 1 March 2023

Alkem Laboratories Limited to Report Q3, 2023 Results on Feb 10, 2023

Does Alkem Laboratories (NSE:ALKEM) Have A Healthy Balance Sheet?

Eight Roads Ventures India Healthcare IV, L.P entered into a Shareholders’ Agreement to acquire a minority stake in Enzene Biosciences Ltd from Alkem Laboratories Limited (BSE:539523) for INR 1614.83 million.

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind